AGE-RELATED MACULAR DEGENERATION THERAPEUTICS MARKET ANALYSIS

Age-Related Macular Degeneration Therapeutics Market, by Drug Type (Ranibizumab, Aflibercept, Bevacizumab, Pegaptanib, Brolucizumab, and Others), by Type (Dry AMD and Wet AMD), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI786
Formats :
Excel and PDF
Industry : Pharmaceutical

Age-Related Macular Degeneration Therapeutics MarketSize and Trends

Global Age-related Macular Degeneration Therapeutics Market – Dynamics

Rising geriatric population is expected to drive the age-related macular degeneration therapeutics market over the forecast period. For instance, according to the World Population Prospects in 2017, global population aged over 60 years was 962 million, which is expected to reach around 2.1 billion by 2050. Globally, population aged 60 or over is increasing at a faster pace compared to all younger age groups. This group of population is highly susceptible to different types of age-related diseases such as diabetes, renal insufficiency, arthritis, and macular degeneration. The risk of getting affected by advanced age-related macular degeneration for people of age group of 50-59 is 2%, whereas it is around 30%, who are over the age of 75.

Moreover, increasing prevalence of age-related macular degeneration is expected to propel the market growth over the forecast period. For instance, according to the BrightFocus Foundation, January 2019, macular degeneration is a leading cause of blindness in the U.S. population aged above 60 years and around 11 million people in the U.S. suffered from macular degeneration, which is expected to double to nearly 22 million by 2050.